Citations

Clear

2303 citation(s) found for "Yu, Edward".

Efficacy and Safety of Filgotinib as Maintenance Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study
Koch, Robert, Sandborn, WJ, Fogel, Ronald, Nijhawan, Sandeep, McNally, J. , Yun, Chohee , Zhao, Sally, Liu, X, Tasset, Chantal , Besuyen, R. , Watanabe, Mamoru , Hibi∥, Toshifumi , Feagan, B., Peyrin‐Biroulet, Laurent , Loftus, Edward V. , Danese, Silvio , Vermeire, Séverine , Kempiński, Radosław , Filip, Rafał , Hospodarskyy, Ihor , Schreiber, Stefan , Rogler, Gerhard

Mayo Clinic

Zeitschrift für Gastroenterologie | November 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1734236 Get It

Efficacy and Safety of Filgotinib as Induction Therapy for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the Phase 2b/3 SELECTION Study
Koch, Robert, Feagan, BC, Sandborn, WJ, Ritter, Timothy E., Mehta, Rajiv , Seidler, Ursula , Seibold, Frank , Kim, H, McNally, J. , Yun, Chohee , Zhao, Sally, Liu, X, Tasset, Chantal , Besuyen, R. , Watanabe, Mamoru , Hibi∥, Toshifumi , Loftus, Edward V. , Danese, Silvio , Vermeire, Séverine , Beales, Ian , Schreiber, Stefan , Rogler, Gerhard , Peyrin‐Biroulet, Laurent

Mayo Clinic

Zeitschrift für Gastroenterologie | November 22, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/s-0041-1734235 Get It

Dramatic Reduction of Distant Pancreatic Metastases Using Local Light Activation of Verteporfin with Nab-Paclitaxel
Pigula, Michael , Mai, Zhiming , Anbil, Sriram , Choi, Myung‐Gyu , Maytin, Edward V. , Hasan, Tayyaba , Hasan, Tayyaba , Wang, Kenneth , Pogue, Brian W.

Mayo Clinic

Cancers | November 18, 2021 | Volume: 13 | Issue: 22 | Pages: 5781

10.3390/cancers13225781 | PMID 34830934 Get It

Despite substantial drug development efforts, pancreatic adenocarcinoma (PDAC) remains a difficult disease to treat, and surgical resection is the only potentially curative option. Unfortunately, 80% of patients are ineligible for surgery due to the presence of invasive disease and/or distant metastases at the time of diagnosis. Treatment strategies geared towards reclassifying these patients as surgical candidates by reducing metastatic burden represents the most promising approach to improve long-term survival. We describe a photodynamic therapy (PDT) based approach that, in combination with the first-line chemotherapeutic nab-paclitaxel, effectively addresses distant metastases in three separate orthotopic PDAC models in immunodeficient mice. In addition to effectively controlling local tumor growth, PDT plus nab-paclitaxel primes the tumor to elicit systemic effects and reduce or abrogate metastases. This combination dramatically inhibits (up to 100%) the eventual development of metastases in models of early stage PDAC, and completely eliminates metastasis in 55% of animals with already established distant disease in late-stage models. Our findings suggest that this light activation process initiates local biological and/or physiological changes within the tumor microenvironment that can be leveraged to treat both localized and distant disease, and potentially reclassify patients with previously inoperable disease as surgical candidates.
How a Virtual Scribe Program Improves Physicians’ EHR Experience, Documentation Time, and Note Quality
Ong, S. , Williams, Brian , O’Connell, Ryan , Goldstein, Richard , Melnick, Edward R. , Melnick, Edward R , Jeffery, Molly Moore

Mayo Clinic

NEJM Catalyst | November 17, 2021 | Volume: 2 | Issue: 12 | Pages: No page available

10.1056/cat.21.0294 Get It

Germline Cancer Susceptibility Gene Testing in Unselected Patients with Hepatobiliary Cancers: A Multi-Center Prospective Study
Usón, Pedro Luiz Serrano , Kunze, Katie L. , Golafshar, Michael A. , Riegert-Johnson, Douglas, Boardman, Lisa A. , Borad, Mitesh J., Ahn, Daniel, Sonbol, Mohamad B., Faigel, Douglas O., Fukami, Norio , Pannala, Rahul, Barrus, Kathleen , Mountjoy, Luke, Esplin, Edward D. , Nussbaum, Robert L., Stewart, A. Keith, Bekaii-Saab, Tanios, Samadder, N. Jewel, Bekaii‐Saab, Tanios , Uson, Pedro L S , Boardman, Lisa , Golafshar, Michael , Esplin, Edward D , Fukami, Norio , Bekaii-Saab, Tanios S , Kunze, Katie L , Riegert-Johnson, Douglas, Borad, Mitesh J., Ahn, Daniel, Sonbol, Mohamad B., Faigel, Douglas O., Pannala, Rahul, Barrus, Kathleen , Mountjoy, Luke, Nussbaum, Robert L., Stewart, A. Keith, Samadder, N. Jewel

Mayo Clinic

Cancer Prevention Research | November 15, 2021 | Volume: 15 | Issue: 2 | Pages: 121-128

10.1158/1940-6207.capr-21-0189 | PMID 34782326 Get It

Abstract Data from germline testing in unselected patients with hepatobiliary cancers are limited. Identification of germline predisposition can have important implications on cancer treatment and family counseling. To determine prevalence of pathogenic germline variants (PGV) in patients with hepatobiliary cancer, we undertook a prospective multi-site study of germline sequencing using a >80-gene next-generation sequencing platform among patients with hepatobiliary cancers receiving care at Mayo Clinic Cancer Centers between April 1, 2018 and March 31, 2020. Patients were not selected on the basis of stage, family cancer history, ethnicity, or age. Family cascade testing was offered at no cost. Of 205 patients, the median age was 65 years, 58.5% were male, 81% were White, and 64.4% had cholangiocarcinoma, 21.5% hepatocellular carcinoma, 7.8% gallbladder cancer, and 4.3% carcinoma of ampulla of Vater. PGV were found in 15.6% (n = 32) of patients, including 23 (71%) in moderate and high penetrance cancer susceptibility genes. A total of 75% of patients with a positive result would not have been detected using guidelines for genetic evaluation. Prevalence of PGV was 15.7% in intrahepatic cholangiocarcinoma, 17% in extrahepatic cholangiocarcinoma, 15.9% in hepatocellular cancer, and 33% in carcinoma of ampulla of Vater. On the basis of these genetic findings, 55% were potentially eligible for approved precision therapy and/or clinical treatment trials. Universal multi-gene panel testing in hepatobiliary cancers was associated with detection of heritable mutations in over 15% of patients most of whom would not have been tested using current guidelines. Germline testing should be considered in all patients with hepatobiliary cancers. Prevention Relevance: Universal multi-gene testing in hepatobiliary cancers was associated with heritable mutations in over 15% of patients, most of whom would not have been tested using current guidelines. 55% were potentially eligible for approved precision therapy and/or clinical treatment trials. Germline testing should be considered in all patients with hepatobiliary cancers.
Remote synchronous toenail procedure training using a sausage model
Stacey, Stephen K , Malone, Edward J.

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | November 15, 2021 | Volume: 11 | Issue: 6 | Pages: 808-811

10.1080/20009666.2021.1976371 | PMID 34804395 Get It

PMO-31 Rapidity of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis
Morison, Ben, Hibi∥, Toshifumi , Ritter, Timothy E., Dinoso, Jason B., Hsieh, Jeremy, Yun, Chohee , Zhao, Sally, Danese, Silvio , Zhang, Jie , Loftus, Edward V. , Rogler, Gerhard

Mayo Clinic

Posters | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A93.1-A93

10.1136/gutjnl-2021-bsg.170 Get It

PMO-30 Corticosteroid-free remission of ulcerative colitis with filgotinib maintenance therapy: post-hoc analysis of the SELECTION study
Morison, Ben, Vermeire, Séverine , Feagan, Brian, Yun, Chohee , Hsieh, Jeremy, Liu, Xiaopeng, Zhao, Sally, Moerch, Ulrik, Sandborn, William J. , Hibi∥, Toshifumi , Vermeire, Séverine , Loftus, Edward V.

Mayo Clinic

Posters | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A92.2-A92

10.1136/gutjnl-2021-bsg.169 Get It

OMO-3 Safety analysis of filgotinib for ulcerative colitis: Phase 2b/3 selection study and long-term extension results
Morison, Ben, Watanabe, Mamoru , Yun, Chohee , Zhao, Sally, Hsieh, Jeremy, Moerch, Ulrik, Schreiber, Stefan , Zhou, Yan, Rogler, Gerhard , Loftus, Edward V.

Mayo Clinic

Oral | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A6.1-A6

10.1136/gutjnl-2021-bsg.10 Get It

TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy
Alquezar, Carolina , Schoch, Kathleen M. , Geier, Ethan G., Ramos, Eliana Marisa , Scrivo, Aurora , Li, Kathy H., Argouarch, Andrea R. , Mlynarski, Elisabeth E. , Dombroski, Beth A. , DeTure, Michael , Yokoyama, Jennifer S. , Burlingame, Alma L. , Schellenberg, Gerard D. , Miller, Timothy M. , Miller, Bruce L. , Dombroski, Beth , Dickson, Dennis W , Cuervo, Ana M , Burlingame, Alma L , Schellenberg, Gerard D , Miller, Timothy M , Miller, Bruce L , Kao, Aimee W. , DeTure, Michael , Yokoyama, Jennifer , Alquezar, Carolina , Dickson, Dennis W.

Mayo Clinic

Science Advances | November 5, 2021 | Volume: 7 | Issue: 45 | Pages: No page available

10.1126/sciadv.abg3897 | PMID 34739309 Get It

TSC1/hamartin haploinsufficiency increases risk for tauopathy by promoting tau acetylation and accumulation.